Trial Profile
Efficacy and safety of initiating or switching to Infliximab biosimilar Ct-P13 in inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 05 Dec 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week